Published: Jul 18, 2026

Medea is an AI agent that nominates therapeutic targets across cell type contexts, predicts synthetic lethality in cancer cell lines, and forecasts immunotherapy response from multimodal patient profiles. To test whether Medea can identify the genetic vulnerabilities that DNA-damaging treatments exploit, we use it to scan 238,046 gene combinations for synthetic lethality. [Project website]